Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended-release Buprenorphine as a Novel Low-dose Induction Strategy
NCT06441604Phase 2Active, not recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Oct 2025
- Primary completion
- Jun 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of buprenorphine extended-release injection in opioid use disorder (OUD), sponsored by Brigham and Women's Hospital. Started Oct 2025; status: active, not recruiting.
02
Drugs
buprenorphine extended-release injection
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT06441604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06441604.